Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.

F. Boccardo, A. U. Decensi, D. Guarneri, G. Martorana, L. Fioretto, E. Mini, M. P. Macaluso, L. Giuliani, L. Santi, P. Periti

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Between March 1986 and March 1987, 48 patients with stage D prostate carcinoma were entered into a multicentric pilot study using the pure nonsteroidal antiandrogen nilutamide (Anandron--RU 23908) at the dose of 100 mg t.i.d. as the only therapy until disease progression or the occurrence of toxicity. Minimum follow-up was 15 months. Median age of patients was 72 (56 to 83) and median initial Performance Status (PS) was 1 (0 to 3). Of the 48 patients, 29 were untreated, while 19 patients were progressing following treatment by orchiectomy, LHRH analogs, or other endocrine therapies. According to the National Prostatic Cancer Project (NPCP) criteria, 43 patients were evaluable for response. Overall best response in untreated patients was partial response (PR), 41.6%; stationary disease (SD), 54.1%; 73.6% of pretreated patients achieved SD. Median progression-free survival and overall survival in untreated patients were 325 and 696 days, respectively, and 174 and 447 days, respectively, in pretreated patients. The more common side effects were G.I. toxicity (65%), hemeralopia (27%), and alcohol intolerance (6.2%). Results of this study suggest that Anandron may be a safe and effective treatment for patients with advanced prostatic cancer.

Original languageEnglish
Pages (from-to)501-503
Number of pages3
JournalCancer Detection and Prevention
Volume15
Issue number6
Publication statusPublished - 1991

Fingerprint

Prostatic Neoplasms
Nonsteroidal Anti-Androgens
nilutamide
Orchiectomy
Vision Disorders
Therapeutics
Gonadotropin-Releasing Hormone
Disease-Free Survival
Disease Progression
Prostate
Alcohols
Carcinoma
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Boccardo, F., Decensi, A. U., Guarneri, D., Martorana, G., Fioretto, L., Mini, E., ... Periti, P. (1991). Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. Cancer Detection and Prevention, 15(6), 501-503.

Anandron (RU 23908) in metastatic prostate cancer : preliminary results of a multicentric Italian study. / Boccardo, F.; Decensi, A. U.; Guarneri, D.; Martorana, G.; Fioretto, L.; Mini, E.; Macaluso, M. P.; Giuliani, L.; Santi, L.; Periti, P.

In: Cancer Detection and Prevention, Vol. 15, No. 6, 1991, p. 501-503.

Research output: Contribution to journalArticle

Boccardo, F, Decensi, AU, Guarneri, D, Martorana, G, Fioretto, L, Mini, E, Macaluso, MP, Giuliani, L, Santi, L & Periti, P 1991, 'Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.', Cancer Detection and Prevention, vol. 15, no. 6, pp. 501-503.
Boccardo, F. ; Decensi, A. U. ; Guarneri, D. ; Martorana, G. ; Fioretto, L. ; Mini, E. ; Macaluso, M. P. ; Giuliani, L. ; Santi, L. ; Periti, P. / Anandron (RU 23908) in metastatic prostate cancer : preliminary results of a multicentric Italian study. In: Cancer Detection and Prevention. 1991 ; Vol. 15, No. 6. pp. 501-503.
@article{fad43306b147409d8d377a7d6ec0f635,
title = "Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.",
abstract = "Between March 1986 and March 1987, 48 patients with stage D prostate carcinoma were entered into a multicentric pilot study using the pure nonsteroidal antiandrogen nilutamide (Anandron--RU 23908) at the dose of 100 mg t.i.d. as the only therapy until disease progression or the occurrence of toxicity. Minimum follow-up was 15 months. Median age of patients was 72 (56 to 83) and median initial Performance Status (PS) was 1 (0 to 3). Of the 48 patients, 29 were untreated, while 19 patients were progressing following treatment by orchiectomy, LHRH analogs, or other endocrine therapies. According to the National Prostatic Cancer Project (NPCP) criteria, 43 patients were evaluable for response. Overall best response in untreated patients was partial response (PR), 41.6{\%}; stationary disease (SD), 54.1{\%}; 73.6{\%} of pretreated patients achieved SD. Median progression-free survival and overall survival in untreated patients were 325 and 696 days, respectively, and 174 and 447 days, respectively, in pretreated patients. The more common side effects were G.I. toxicity (65{\%}), hemeralopia (27{\%}), and alcohol intolerance (6.2{\%}). Results of this study suggest that Anandron may be a safe and effective treatment for patients with advanced prostatic cancer.",
author = "F. Boccardo and Decensi, {A. U.} and D. Guarneri and G. Martorana and L. Fioretto and E. Mini and Macaluso, {M. P.} and L. Giuliani and L. Santi and P. Periti",
year = "1991",
language = "English",
volume = "15",
pages = "501--503",
journal = "Cancer Detection and Prevention",
issn = "0361-090X",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Anandron (RU 23908) in metastatic prostate cancer

T2 - preliminary results of a multicentric Italian study.

AU - Boccardo, F.

AU - Decensi, A. U.

AU - Guarneri, D.

AU - Martorana, G.

AU - Fioretto, L.

AU - Mini, E.

AU - Macaluso, M. P.

AU - Giuliani, L.

AU - Santi, L.

AU - Periti, P.

PY - 1991

Y1 - 1991

N2 - Between March 1986 and March 1987, 48 patients with stage D prostate carcinoma were entered into a multicentric pilot study using the pure nonsteroidal antiandrogen nilutamide (Anandron--RU 23908) at the dose of 100 mg t.i.d. as the only therapy until disease progression or the occurrence of toxicity. Minimum follow-up was 15 months. Median age of patients was 72 (56 to 83) and median initial Performance Status (PS) was 1 (0 to 3). Of the 48 patients, 29 were untreated, while 19 patients were progressing following treatment by orchiectomy, LHRH analogs, or other endocrine therapies. According to the National Prostatic Cancer Project (NPCP) criteria, 43 patients were evaluable for response. Overall best response in untreated patients was partial response (PR), 41.6%; stationary disease (SD), 54.1%; 73.6% of pretreated patients achieved SD. Median progression-free survival and overall survival in untreated patients were 325 and 696 days, respectively, and 174 and 447 days, respectively, in pretreated patients. The more common side effects were G.I. toxicity (65%), hemeralopia (27%), and alcohol intolerance (6.2%). Results of this study suggest that Anandron may be a safe and effective treatment for patients with advanced prostatic cancer.

AB - Between March 1986 and March 1987, 48 patients with stage D prostate carcinoma were entered into a multicentric pilot study using the pure nonsteroidal antiandrogen nilutamide (Anandron--RU 23908) at the dose of 100 mg t.i.d. as the only therapy until disease progression or the occurrence of toxicity. Minimum follow-up was 15 months. Median age of patients was 72 (56 to 83) and median initial Performance Status (PS) was 1 (0 to 3). Of the 48 patients, 29 were untreated, while 19 patients were progressing following treatment by orchiectomy, LHRH analogs, or other endocrine therapies. According to the National Prostatic Cancer Project (NPCP) criteria, 43 patients were evaluable for response. Overall best response in untreated patients was partial response (PR), 41.6%; stationary disease (SD), 54.1%; 73.6% of pretreated patients achieved SD. Median progression-free survival and overall survival in untreated patients were 325 and 696 days, respectively, and 174 and 447 days, respectively, in pretreated patients. The more common side effects were G.I. toxicity (65%), hemeralopia (27%), and alcohol intolerance (6.2%). Results of this study suggest that Anandron may be a safe and effective treatment for patients with advanced prostatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026285040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026285040&partnerID=8YFLogxK

M3 - Article

C2 - 1782640

AN - SCOPUS:0026285040

VL - 15

SP - 501

EP - 503

JO - Cancer Detection and Prevention

JF - Cancer Detection and Prevention

SN - 0361-090X

IS - 6

ER -